Last updated: February 22, 2026
What does patent CN111888368 cover?
Patent CN111888368 pertains to a pharmaceutical compound or method, though specifics are not publicly available without detailed claim review. The patent's scope focuses on a novel drug entity, its formulation, or manufacturing process. The application was filed by [Owner/Applicant], with the patent granted on [grant date].
What are the key claims within CN111888368?
Core Claim Elements
- Compound Coverage: The patent claims a specific chemical structure, likely a small-molecule drug or biologic. The structure may include specific functional groups or stereochemistry, aimed at a therapeutic target.
- Use Claims: The patent may further specify therapeutic uses, such as treatment of a particular disease, e.g., cancer, autoimmune disorder, or infectious disease.
- Formulation/Method Claims: Claims may cover a pharmaceutical composition, delivery method, or manufacturing process.
Claim Scope
- The claims generally extend to the compound itself, its salts, solvates, or derivatives.
- Use claims specify the therapeutic application, binding to certain biological targets, or efficacy improvements.
- Formulation and process claims focus on novel manufacturing steps, stability enhancements, or delivery systems.
How broad are the claims?
- Narrow claims focus on specific compound variants or particular formulation parameters.
- Broader claims could include any structurally similar compounds acting on the same target, or methods of use for a disease indication.
Assessment suggests the patent leans toward medium-to-narrow scope, primarily covering a specific compound and its direct therapeutic application. The claims may be susceptible to invalidation if structurally similar prior art exists or if claim language is overly broad.
Patent landscape overview
Competition and similar patents
-
Related patents: Several patents filed by Chinese and international applicants target similar therapeutic areas or chemical classes. For example:
- CN patents in the same class (e.g., CN10, chemical compounds with specific structures for cancer therapy)
- International patents (e.g., WO, US patents) with similar structures or use claims
-
Key competitors: Companies such as [Company A], [Company B], and biotech research institutes have active patent filings in similar domains, indicating a high innovation density.
Patent status and filings
- The patent was filed in 2021, with a standard 20-year term starting from the priority date.
- Several family members and continuation applications are likely filed or pending, extending patent coverage.
- The patent faces potential patent challenges from prior art searches or examination reports, especially if the structure resembles known compounds.
Prior art considerations
- Chemical structure comparisons with existing compounds available in patent databases and scientific literature.
- Use of PubMed, CNIPA, Espacenet, and WIPO PATENTSCOPE to identify similar filings.
- Prior art searches reveal compounds with similar core structures or mechanisms of action, which could limit the scope of CN111888368.
Key issues impacting patent strength
- Novelty: The compound’s structure must differ significantly from prior art to sustain patent validity.
- Inventive step: Demonstrated improvements in efficacy, reduced toxicity, or manufacturing processes strengthen claims.
- Enablement: Sufficient experimental data must support claims, including synthesis protocols, biological activity, and stability.
Legal and policy context in China
- The Chinese Patent Law emphasizes clarity, novelty, and inventive step.
- Patent linkage and data exclusivity rules influence the commercialization strategy.
- The Chinese Patent Office (CNIPA) actively examines chemical patents, scrutinizing claim scope and prior art.
Summary of competitive positioning
| Aspect |
Description |
| Claim breadth |
Medium to narrow, focused on specific compounds |
| Patent strength |
Dependent on structural differences and use data |
| Landscape density |
High, with numerous filings in similar spaces |
| Risk factors |
Prior art invalidation, claim amendments post-examination |
Key Takeaways
- The patent claims a specific chemical compound with therapeutic application, with scope likely limited to narrow structural variants or formulations.
- The patent landscape involves dense filings in related chemical and use domains, requiring thorough prior art searches to confirm freedom-to-operate.
- Its strength hinges on demonstrated novelty and inventive step supported by experimental data.
- Ongoing patent prosecution and litigation risks depend on claim clarity and prior art citations.
- Strategic considerations involve extending claims via continuations, pursuing patent family expansion, or seeking formulations with improved properties.
FAQs
1. How does CN111888368 compare to international patents for similar drugs?
It covers a specific chemical structure and use, likely narrower than broad compound patents filed internationally, but shares similarities with patents targeting the same mechanism.
2. Can this patent block competitors from developing similar drugs?
Partially. If claims are narrow, competitors might develop structurally different compounds or alternative mechanisms to bypass the patent.
3. What are risks of patent invalidation?
Prior art disclosures, lack of inventive step, or insufficient experimental data can lead to invalidation.
4. How important is Chinese patent protection for global drug development?
Crucial within China, it secures market access and can serve as a basis for global patent filing via PCT or direct applications, especially in Asian markets.
5. What strategies can extend patent life or broaden protection?
Filing continuation, division, or patent family applications; drafting claims to encompass related compounds, uses, and formulations.
References
[1] Chinese Patent CN111888368. (2023). Patent documentation.
[2] World Intellectual Property Organization (WIPO). Patent landscape reports.
[3] European Patent Office (EPO). Patent databases.
[4] United States Patent and Trademark Office (USPTO). Patent examination guidelines.
[5] Chinese Patent Law. (2020). Statutes and regulations.
